Stock Ratings / Health Care / BBOT / options

NATR (68) KRRO (44) SLGL (54) KROS (66) ⌘ Pro Terminal →

BridgeBio Oncology Therapeutics Inc. (BBOT) Options Positioning, Max Pain & Unusual Sweeps

Q: Where is BBOT trading relative to its 50-day, 200-day, and 52-week technical levels?

BBOT last traded at $2.62 (-2.96% on volume of 314,789 shares), positioning the stock -47.60% below its 50-day simple moving average ($5.00) and -67.77% below its 200-day simple moving average ($8.13). Across its 52-week range of $2.51 to $14.87, BBOT sits at the 0.9% percentile with a 14-day RSI of 24.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.29 to $2.95).

Q: What is BBOT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BBOT.

$2.62 -2.96% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.60

BridgeBio Oncology Therapeutics Inc. (BBOT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $216.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BBOT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BBOT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $2.62 (-2.96% 1D, market cap $216.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, BBOT ranks #612 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BBOT compare to NATR and KRRO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BBOT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NATR (Nature's Sunshine Products Inc.) holds a C+ grade (68/100 RQD, P/E 11.1x, ROIC 28.9%, cap $216.1M) and KRRO (Korro Bio Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $209.1M). Among the 5-stock peer group, NATR leads on earnings multiple (11.1x) while KROS leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BBOT?

▼

Per BBOT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001869105), BridgeBio Oncology Therapeutics Inc. generated $0 in revenue, -$134.0M in net income, and -$114.5M in free cash flow against $448.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $2.60 (-0.72%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-9.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BBOT)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (37/100 Composite)

🔍 WHY BBOT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (27% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (27% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 24.1 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.31-14.8% Next Q

Q2 (-2Q)

Grade D$2.82-5.7% Next Q

Q3 (-1Q)

Grade D$2.66-1.5% Next Q

Current

Grade D-$2.62-8.1% Hist 90D α

Trajectory: D (45) → D- (37)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BBOT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BBOT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.00) and Max Pain ($2.75) forces dealer call-delta covering toward $15.61.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BBOT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BBOT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 37%NO 63%Trade / Inspect Odds →

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (BBOT)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for BBOT.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BBOT)

✓Walkthrough of BBOT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BBOT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -68.85%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.70H $2.74L $2.61C $2.62VOL 314.8K

RES: $10.20SUP: $2.38SMA50: $5.00SMA200: $8.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BBOT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BBOT Butterfly Map → + Track BBOT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BBOT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BBOT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BBOT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BBOT)

Health Care Rank #612 of 1016 ⚔️ NATR vs BBOT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BBOT vs. NATR, KRRO, SLGL, KROS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BridgeBio Oncology Therapeutics Inc. (BBOT) ranks #612 by composite RQD confidence (37/100, grade D-) and #563 by equity capitalization ($216.5M). Within this direct 5-issuer industry benchmark cohort, NATR leads on earnings valuation at 11.1x trailing P/E, while KROS leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. NATR currently holds the highest overall quantitative score in the immediate peer group at 68/100 (C+) compared with BBOT at 37/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BBOT ACTIVE BridgeBio Oncology Therapeutics Inc.	D-	37/100	—	—	-35.0%	-2.96%	$216.5M	Benchmark Subject
NATR Nature's Sunshine Products Inc.	C+	68/100	11.1x	72.4%	28.9%	-0.24%	$216.1M	/natr-vs-bbot →
KRRO Korro Bio Inc.	D	44/100	—	—	-35.0%	+0.81%	$209.1M	/krro-vs-bbot →
SLGL Sol-Gel Technologies Ltd.	D+	54/100	—	—	-35.0%	-0.45%	$224.8M	/slgl-vs-bbot →
KROS Keros Therapeutics Inc.	C+	66/100	—	—	85.0%	-2.82%	$225.2M	/kros-vs-bbot →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001869105

In its most recent audited fiscal period (FY2025, filed 2025-12-31), BridgeBio Oncology Therapeutics Inc. (BBOT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$134.0M, operating cash flow of -$113.9M, and free cash flow of -$114.5M (-107.9% YoY). On the balance sheet, BBOT closed FY2025 with $448.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$134.0M	-$113.9M	-$114.5M	$448.4M	—
FY2024 (FY)	2024-12-31	$0	-$74.3M	-$55.0M	-$55.1M	$164.3M	—
FY2023 (FY)	2023-12-31	$0	-$41.7K	—	—	—	—

3. BBOT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BBOT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does BBOT compare to NATR and KRRO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for BBOT?

Where is BBOT trading relative to its 50-day, 200-day, and 52-week technical levels?

BBOT last traded at $2.62 (-2.96% on volume of 314,789 shares), positioning the stock -47.60% below its 50-day simple moving average ($5.00) and -67.77% below its 200-day simple moving average ($8.13). Across its 52-week range of $2.51 to $14.87, BBOT sits at the 0.9% percentile with a 14-day RSI of 24.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($2.29 to $2.95).

BBOT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is BBOT's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for BBOT.

Direct Sub-Reports: BBOT RQD Cockpit BBOT 12M Forecast BBOT Earnings & Move BBOT Dividends & DRIP BBOT Insiders & 13F BBOT Whale Options BBOT Profit Sankey BBOT News & Why

ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

BBOT — BridgeBio Oncology Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:40:48Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BBOT scores 37 out of 100, earning a D- grade and the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 6 / 20. Per the RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow to support valuation on earnings or cash-flow grounds.
Whale 13F Flow: 6 / 20. The rating references institutional accumulation and options positioning. No holder-level detail is provided in the holders section, so the weight of this pillar cannot be independently verified here.
Insider Conviction: 5 / 20. The rating references SEC Form 4 and Congressional PTR cluster flow, scoring low. Specific trade records are not provided in the source data.
Macro Regime Fit: 10 / 20. Per the RQD rating, beta is 1.0 and the rating reflects sector sensitivity. The stock is assessed as moving in line with the broader market rather than offering defensive characteristics.
Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These readings indicate moderate but not strong financial health.

Taken together, the low scores on cash generation and insider conviction are the main weights against the stock. Upside drivers, as framed in the source data, would need to come from improved cash-flow generation, which the current financials do not show. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in source data. A prospective investor would be weighing a company with negative returns and no current free-cash-flow yield against a cash balance and moderate forensic scores.

Business

BridgeBio Oncology Therapeutics Inc. (BBOT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.2B. The source data does not describe its products, customers, or revenue model. Reported revenue is $0.0M for each period shown in the SEC financials.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-145.8M	$-134.0M	N/A	$-114.5M	$373.7M	N/A
FY 2024	$0.0M	$-80.9M	$-74.3M	N/A	$-55.1M	$30.9M	N/A
FY 2023	$0.0M	$-0.0M	$-0.0M	N/A	N/A	N/A	N/A

Per the SEC financials, the company reported operating losses in FY 2025 and FY 2024, with net losses of $-134.0M and $-74.3M respectively. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9. Reported cash rose from $30.9M to $373.7M between FY 2024 and FY 2025, and debt is listed as N/A in both periods; Debt/Equity is 0.5 per the RQD rating.

Recent Catalysts & News Wire Analysis

Per the recent news section, the following items were reported:

Analyst action (GREEN, CATALYST): An Oppenheimer price target adjustment to $16 from $22 with an Outperform rating was reported.
Seeking Alpha (YELLOW, MARKET WIRE): A report discussing a KRAS opportunity following a selloff.
TradingView (YELLOW, MARKET WIRE): An estimates-focused report.
The Globe and Mail (YELLOW, MARKET WIRE): A report stating Piper Sandler remains a Buy.
Stock Titan (YELLOW, MARKET WIRE): A report of 343 shares withheld for taxes, leaving the COO with 14,152 shares.
MarketBeat (YELLOW, MARKET WIRE): A report of a consensus "Moderate Buy" rating.

Per the butterfly supply-chain graph, no supply-chain relationship is recorded (supply_chain: NONE), and no butterfly links or proprietary signals are provided. Risk watch items drawn from the data include the 52-week range of $2.51 to $14.87 against the current price of 2.62, and the -2.96% change on the day.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply_chain is NONE and no butterfly links are recorded. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data. The sector is listed as Health Care and the industry as Biotechnology: Pharmaceutical Preparations. Beyond these classifications, the sources provide no specific dependency mapping. A prospective investor should treat any ripple analysis for this company as unavailable in source data.

Analyst View & Smart Money Ownership

Per the analyst data section, the input is NONE, so consensus ratings and price targets from that section are not available in source data. Per the news section, MarketBeat reports a consensus rating of "Moderate Buy," Oppenheimer's price target is $16 with an Outperform rating, and Piper Sandler is reported as a Buy.

Per the holders section, the input is NONE. SEC Form 4 insider transactions, 13F institutional holdings, and Congressional trades cannot be itemized from the source data. The RQD rating references institutional accumulation and insider cluster flow, but the underlying holder records are not provided.

Open Questions

What products or clinical programs generate the company's activity, given that reported revenue is $0.0M in each period?
What explains the swing in reported cash from $30.9M in FY 2024 to $373.7M in FY 2025, and what is the company's runway at the FY 2025 burn rate of $-114.5M in FCF?
What is the source of the debt/equity figure of 0.5 when the debt line is N/A in the SEC financials?
What are the specific SEC Form 4, 13F, and Congressional trades underlying the insider and whale pillar scores?
Why are forward and trailing earnings multiples unavailable, and what would EV/EBITDA look like on a complete data set?

BBOT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BridgeBio Oncology Therapeutics Inc. (BBOT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BBOT Debate Forum (3) ↓

🟢 CATALYST Yahoo Finance • 6h ago

Oppenheimer Adjusts Price Target on BridgeBio Oncology Therapeutics to $16 From $22, Maintains Outperform Rating

Yahoo Finance report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Seeking Alpha • 9h ago

BridgeBio Oncology: The KRAS Opportunity Hidden In The Selloff (NASDAQ:BBOT)

Seeking Alpha report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 12h ago

BridgeBio Oncology Therapeutics, Inc. Estimates – NASDAQ:BBOT

TradingView report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE The Globe and Mail • 15h ago

Piper Sandler Remains a Buy on BridgeBio Oncology Therapeutics (BBOT)

The Globe and Mail report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

343 shares withheld for taxes leave BridgeBio Oncology (BBOT) COO with 14,152 shares.

Stock Titan report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 21h ago

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Rating of "Moderate Buy" from Analysts

MarketBeat report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST MarketBeat • 1d ago

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Upgraded to "Sell" at Wall Street Zen

MarketBeat report covering BridgeBio Oncology Therapeutics Inc. (BBOT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BBOT Bull vs. Bear Conversation Board — What's Your Call at $2.62?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BBOT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $2.31 (-11.8%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is BBOT (D- • RQD 37/100) a Buy at $2.62?

Welcome to the BBOT (BridgeBio Oncology Therapeutics Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.99 (-24.0%)

Spot @ $2.62

Pump the brakes on BBOT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BBOT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless BridgeBio Oncology Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH 🎯 Target: $3.20 (+22.1%)

Spot @ $2.62

BBOT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BBOT, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $2.62 (52-wk range $2.51 - $14.87), any beat on forward guidance forces shorts and underweight funds to chase.